New therapies are in development for COPD (endobronchial valves/stents/glue) and asthma (endobronchial thermal ablation). Hyperpolarized xenon-129 (HXe) MRI, a noninvasive method to assess regional lung structure and function, may prove critical in the guidance of these regional treatments. In our prior work we developed an innovative approach to xenon polarization that provides the liter quantities of highly polarized xenon-129 as required for medical imaging. Our prototype system was deployed at UVa where we performed 600 experiments in 64 patient and healthy volunteers and made significant advances in MR acquisition strategies and image quality. These promising results enable us to move to the next step in the commercialization of HXe, the performance of a Phase 2 clinical trial. Our goals for Phase 2 are to collect safety endpoints in patients with obstructive lung diseases, finalize the HXe dosing and MRI methods, and validate the HXe results by comparing with the existing clinical methods for assessing lung function and microstructure. We selected the two most mature and promising HXe techniques for inclusion in the Phase 2 trial: ventilation and diffusion imaging. Obstructive lung diseases such as COPD and asthma have been shown to have regional abnormalities of ventilation and these abnormalities are prime targets for intervention. Thus our first aim is to validate HXe MRI for the intended use of delineating ventilated and unventilated regions of the lung in COPD and asthma patients. For our Phase 2a trial we will compare HXe ventilation MRI and 99Tc DTPA ventilation scintigraphy (a clinical standard for assessing regional lung ventilation) in 10 healthy volunteers and 70 patients with COPD and asthma. In addition to the patient safety data, we will assess total lung volume and ventilated lung volume on MRI, and the congruence of ventilated volume boundaries between HXe MRI and scintigraphy. Recently completed pilot studies show that hyperpolarized helium diffusion imaging with six b-values can separately determine diffusion coefficients along and transverse to acinar ducts, which are related to alveolar depth and duct diameter.
Our second aim i s to validate HXe diffusion MR for the intended use of quantifying alveolar enlargement in emphysema, a fundamental abnormality that currently is assessed only by histology. For our Phase 2b trial we will perform diffusion HXe MRI in vivo in 18 COPD patients scheduled for lung transplant, and repeat the scan in the ex vivo lung after it is removed, thereby establishing that in vivo and ex vivo HXe measurements are concordant. The final step in the validation of the HXe diffusion measurement is to regionally compare alveolar size with morphometric measurements via histology from the explanted lung. The final portion of the proposed work is to raise quality to Phase 3 level, design a draft Phase 3 trial, meet with the FDA for a pre-Phase 3 meeting, and incorporate the FDA input into the Phase 3 protocol. The completion of the proposed work represents a significant advancement towards commercialization of HXe.

Public Health Relevance

The development of treatments that cure lung diseases has been slowed by the lack of a method for obtaining regional and quantitative information about lung function, especially in obstructive disease. Hyperpolarized xenon MRI is a safe and cost-effective imaging modality that has the potential to meet this need. Once hyperpolarized xenon becomes FDA approved and commercially available, this new MRI contrast agent will improve care and reduce costs in two ways: (1) regional maps of lung function acquired using HXe MRI will guide newly emerging bronchoscopic interventions, and (2) utilization of HXe MRI in drug and medical device clinical trials will improve their statistics and reduce their time-to- market. We propose two prospective controlled FDA Phase 2 clinical trials that will provide data on safety and efficacy endpoints for these intended uses.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HL087550-05
Application #
8323129
Study Section
Special Emphasis Panel (ZRG1-CVRS-H (11))
Program Officer
Croxton, Thomas
Project Start
2007-04-01
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$974,748
Indirect Cost
Name
Xemed, LLC
Department
Type
DUNS #
152959891
City
Durham
State
NH
Country
United States
Zip Code
03824
Tustison, Nicholas J; Avants, Brian B; Lin, Zixuan et al. (2018) Convolutional Neural Networks with Template-Based Data Augmentation for Functional Lung Image Quantification. Acad Radiol :
Chang, Yulin V; Quirk, James D; Ruset, Iulian C et al. (2014) Quantification of human lung structure and physiology using hyperpolarized 129Xe. Magn Reson Med 71:339-44
Dregely, Isabel; Ruset, Iulian C; Wiggins, Graham et al. (2013) 32-channel phased-array receive with asymmetric birdcage transmit coil for hyperpolarized xenon-129 lung imaging. Magn Reson Med 70:576-83